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Gut Neuroendocrine Disease
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Gastrointestinal endocrinology as a basic and clinical science has expanded
substantially since the early days of Bayliss and Starling. The peptide chemistry
period was followed by the immunocytochemistry period, and at present we have
moved into the molecular biology era. In retrospect, relatively little progress has
been made in our understanding and treatment of the common gastrointestinal
diseases, while considerable knowledge has accumulated in regard to the rare gut
neuroendocrine tumors. Currently, assay determination oftumor markers has made
tumor diagnosis and localization a well-established routine at most medical institu-
tions. The study oftumortissue has also played an important role in allowingfurther
characterization of these lesions, e.g., purification ofpeptides normally occurring in
low concentration, isolation of peptide mRNA, and studies of receptor binding and
activation.
The increased understanding of the nature of the area of hormone receptors/
receptor binding has enabled the pharmaceutical engineering ofnew molecules with
potent and durable agonist or antagonist actions. An excellent example is the
somatostatin analog, octreotide, which effectively suppresses hormone secretion and
has become avaluable therapeutic principle in gut neuroendocrine disease [1].
Surgery still remains the first option in the treatment of solid tumors (Fig. 1).
Treatment of disseminated metastatic disease continues to be a matter of some
controversy: expectance, chemotherapy, tumor ischemia, interferons, or somato-
statin analogs have all been studied. Due to the relative rarity of these tumors, the
clinical series of treatment evaluations are generally small, and comparison has
usually utilized historical controls. Most recently, randomized multi-center trials
have, however, been established and will no doubt produce valuable recommenda-
tions [2].
Another important issue is monitoring of the effectiveness of therapy: traditional
tumor responses have been followed either radiologically (size) or biochemically by
plasma levels oftumormarkers. Some difficulties arise in this respect, since the novel
treatment strategies may modulate hormone secretion without corresponding anti-
proliferative effects. Also, the sensitivity oftumor imagingvaries among the different
radiological techniques used. These problems are some of the topics that require
further evaluation.
Perspectives in ClinicalResearch
Partofthe discrepancy in progress between the basic and clinical fields maybe due
to the fact that, to date, interest has predominantly focused on the mature peptide
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FIG. 1. To obtain optimal tumor reduction, all patients
with midgut carcinoid syndrome were first treated surgically
(one or two operations). This procedure resulted in total
remission in 25 percent of the patients (cf. [2]). Patients with
residual liver disease underwent subsequent embolization of
the hepatic arteries and also received octreotide (100-200 p.g
daily) for palliation. With this combined treatment, half of
the patients showed objective regression of their liver metas-
tases (i.e., >50 percent size reduction), accompanied by a
substantial decrease in plasma levels of tumor markers for
long periods (cf. Fig. 3). It is likely that this anti-tumor effect
in responsive patients is multifactorial (tumor ischemia, sup-
pression of tumor growth, by octreotide and probably further
unknown factors).
produced by the normal endocrine cell. In the study ofthe diseased endocrine cell, it
is likely that the synthesis of precursors may be equally important. Thus, future
directions will probably include the development of processing-independent assays
measuring the entire translation product [3].
The large number of tumor-produced peptides, amines, enzymes, granule, or
membrane components detected in plasma and tissue samples have, in general, a low
efficacy when used to distinguish the metastatic potential of a lesion. This impedi-
ment may suggest that these compounds have little to do with cell proliferation,
invasiveness, or metastasis formation [4]. The first search for tumor markers was
directed toward identification of the classical amines and peptide hormones associ-
ated with the clinical syndromes. The second search was focused on markers
reflecting theneuroendocrine origin ofthe tumors (neuron-specific enolase, chromo-
granins, synaptophysin). It is likely that the third search will lead us to growth
regulators and gene products. In this regard, the multiple endocrine neoplasia
(MEN) syndromes and specific animal models (Mastomys) will be of benefit in
enabling the study ofthe transformation ofendocrine cells into neoplastic cells. The
concomitant evaluation of gene products, growth factor expression, and hormone
production should provide important information.
A further area of human clinical advance relates to the mapping of the gene
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defects in the MEN syndromes. A significant contribution in this area will lead to
diagnosis of at-risk individuals and allow re-evaluation of the difficult problems of
prophylactic surgery versus reliable monitoring ofthe transition ofendocrine hyper-
plasia into neoplasia. My perspective ofthe clinical future in neuroendocrine tumors
relates to three main areas: tumor cell receptors, growth factors, and immunology.
Tumor CellReceptors
The identification ofsomatostatin receptors on gut endocrine tumor cells led to an
evaluation oftheir possible clinical utility [5]. The development ofthe novel imaging
techniques (iodine- or indium-labeled somatostatin analogs) has generated signifi-
cant new diagnostic perspectives. Thus, in vivo and in vitro demonstration of
somatostatin receptors not only serves diagnostic purposes but may also guide
potential treatment [6]. It is probable that these imaging techniques will not be
limited to somatostatin receptors alone. Accordingly, a likely possibility may be the
imaging of other receptors, for example, growth factors. The development of this
investigative modality may be more viable than tumor labeling with monoclonal
antibodies, which recognize domains that are often relatively nonspecific.
Growth Factors
A role of tumor-produced growth factors as paracrine or autocrine modulators of
tumor cell growth was originally proposed by Sporn and Todaro [7]. Endocrine
tumors have been reported to produce a number ofdiverse growth factors, including
transforming growth factor a and , (TGF), fibroblast-stimulating growth factor
(FGF), platelet-derived growth factor (PDGF), and probably also nerve growth
factor (NGF)-like molecules. In our laboratory, we have demonstrated that human
midgutcarcinoids contain and secrete insulin-like growth factor I (IGF-I) (Fig. 2). In
tumors which exhibited IGF-I receptors, that is, those possessing a complete
autocrine loop, exogenous IGF resulted in a substantial mitogenic effect, which was
significantly reduced by octreotide [8]. Thus, cell culture studies may be a useful
model to investigate the possible mode ofanti-proliferative action for octreotide and
other similar agents in individual tumors.
The hypothesis of a constitutive hypersecretion of IGFs from neuroendocrine
tumors isfurther supportedby studies onpheochromocytomas. These tumors exhibit
an inverse expression of IGF, with almost exclusive production of IGF-II [9]. The
human genes of IGF-I and -II have been mapped to chromosomes 11 and 12 in
regions carrying the proto-oncogenes of the ras family [10,11]. More recently,
overexpression ofIGF-I has been correlated with specific chromosome translocation
in individual neuroendocrine tumors [12].
Immunology
Natural killer (NK) cells have an important function in the defense against
neoplasms. Depressed NK-cell activity has been noted after injury and attributed to
the hormones released by the stress response [13]. In patients with neuroendocrine
tumors, the NK-cell activity can be augmented in patients responsive to treatment
with recombinant gamma interferon. Recent studies have suggested that the NK-cell
activity is independent of the individual hormones produced by the tumor and that
the course maybe reflected by the NK-cell activity [14].
Rosenberg et al. [15,16] recently commented on the biological significance and
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FIG. 2 Immunocytochemical demonstration of IGF-I (A) and its receptor (D) in cultured midgut
carcinoid tumor cells. Consecutive sections from a surgical biopsy of a midgut carcinoid, showing positive
reactions with antisera against IGF-I (C) and proliferating cell nuclear antigen-cyclin (B), respectively.
Note that the proliferating cells contain IGF-I (co-existence between IGF-I and PCNA), suggesting an
autocrine role of IGF-I (cf. (8]). Bars indicate 20 microns.
potential therapeutic implications of tumor-infiltrating lymphocytes (TIL cells) in
metastases of advanced melanomas. If TIL cells were isolated from tumor biopsies
by culture in the presence ofexogenous interleukin 2 (IL-2), TILcells were activated
with IL;, but maintained intact tumor recognition. When these activated TIL cells
were administered to the patient marked tumor regression was observed in individ-
ual patients Liver metastases ofmidgut carcinoid tumors are also infiltrated by TIL
cells, and IL 2 is contained within tumor cells (Fig. 3). We have hypothesized thatGUT NEUROENDOCRINE DISEASE 535
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FIG. 3. Top: Urinary 5-HIAA studied over time in patients with midgut carcinoid
syndrome (bilobar hepatic disease) subsequent to embolization therapy
(mean ±+ SEM). Group I (open circles) showed objective tumor regression on CT
scan, and group II (solid circles) did not. Three patients (arrows) in group II were
excluded due to tumor progression. No patient in group I showed progressive
hepatic disease. Bottom: Immunocytochemical demonstration of TIL cells in
liver metastases of a midgut carcinoid tumor, using monoclonal antibodies. In-
set. After cell culture (three months), IL-2 immunoreactive material was demon-
strated in cytoplasmic granules of tumor cells, indicating endogenous synthesis of
IL-2. Bars indicate 25 microns.536 HAKAN AHLMAN
embolization and secondary tumor ischemia may liberate TIL cells and endogenous
cytokines from ischemic lesions. This process would theoretically result in an
enhanced immunological response against the tumor and would support the excel-
lent clinical response noted in certain patients consequent upon embolization.
Further studies are needed to elucidate the scientific and clinical application ofsuch
potentially useful mechanisms.
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